SYSTEMIC SCLERODERMA TREATMENT MARKET ANALYSIS

Systemic Scleroderma Treatment Market Size and Trends

The systemic scleroderma treatment market is estimated to be valued at USD 1.71 Bn in 2024 and is expected to reach USD 2.39 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.

Discover market dynamics shaping the industry request sample copy

The systemic scleroderma treatment industry is experiencing significant growth driven by the rising incidence of the disease and increased government funding for research. As awareness of systemic scleroderma expands, more patients are seeking treatment options, leading to a higher demand for effective therapies. Government initiatives and funding are facilitating research and development of new treatments, further propelling the market expansion. However, challenges such as the lack of curative therapies and high costs associated with advanced treatments may restrain the market growth.

Discover high revenue pocket segments and roadmap to it: Get instant access to report

Insights By Drug Class - Innovation drives immunosuppressant segment’s dominance

In terms of drug class, immunosuppressant segment is expected to contribute the highest market share of 35.3% in 2024, due to ongoing innovations in drug development. Immunosuppressants are crucial for modulating the immune system. Substantial investments by leading pharmaceutical companies in research and development have led to novel therapies, including biosimilars and specialty drugs like mycophenolate mofetil and cyclophosphamide, which target B and T cells effectively.

Insights By Type - Awareness drives limited scleroderma segment’s dominance 

In terms of type, limited scleroderma segment is expected to contribute the highest market share of 45.2% in 2024. Increasing disease awareness and the rising prevalence of systemic scleroderma are driving this segment growth. Moreover, earlier diagnosis of this autoimmune disease contributes to this segment growth.

Insights By Route of Administration - Convenience leads oral segment’s dominance

In terms of route of administration, oral segment is expected to contribute the highest market share of 69.2% in 2024, due to convenience in administration. Systemic scleroderma poses challenges with frequent medical interventions leading to poor medication adherence. However, oral drugs provide hassle-free self-administration at home settings. This has boosted preference over injectable drugs requiring hospital visits. 

Regional Insights

To learn more about this report, request sample copy

Dominating Region: North America

North America is expected to hold the highest market share of 39.2% in 2024. This can be attributed to a strong presence of leading pharmaceutical companies and growing research and development activities in the region.

Fastest-Growing Region: Asia Pacific

The Asia Pacific region exhibits the fastest growth with 23.6% market share in 2024 and is expected to emerge as a lucrative market in coming years. This can be attributed to rising healthcare expenditure, growing medical tourism industry, and increasing focus of global players to tap into developing healthcare markets.

Systemic Scleroderma Treatment Market Outlook for Key Countries

Increasing product launches/approvals in the U.S.

U.S. systemic scleroderma treatment industry is largely fueled by new product approvals and launches. Companies are significantly expanded treatment options, enhancing patient access to innovative therapies. This dynamic environment fosters competition and encourages ongoing advancements in treatment methodologies, ultimately benefiting patients and healthcare providers alike.

High disease prevalence in Japan

Japan plays a crucial role in the systemic scleroderma treatment industry, driven by its high disease prevalence and a strong emphasis on developing orphan drugs. The country's optimized regulatory pathways facilitate quicker access to innovative therapies, enhancing treatment options for patients. This focus on rare diseases fosters significant investment in research and development, further propelling market growth.

China’s high patient population and high prevalence of the disease

China remains a leading market for systemic scleroderma treatment, largely due to its significant patient population and high prevalence of the disease. This demographic presents key opportunities for stakeholders to enhance their presence in the region. Ongoing research and development efforts focused on innovative therapies further strengthen the market's potential, attracting investment and fostering collaboration among healthcare providers.

India’s favorable regulatory guidelines

The India systemic scleroderma treatment sector is rapidly expanding, driven by favorable regulatory guidelines and the increasing medical needs of a large patient population. The government's supportive policies facilitate quicker access to innovative therapies, while the growing awareness of systemic scleroderma prompts more patients to seek effective treatment options, further boosting market growth.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Get instant access to report

Top Strategies Followed by Systemic Scleroderma Treatment Market Players:

• Established Players: Leading companies are investing heavily in research and development to come up with novel treatment options. They are conducting clinical trials to test new drug candidates and devices. This helps them launch innovative products in the market and maintain leadership.
• Mid-Level Players: Medium-sized companies are focusing on developing affordable treatment alternatives targeting price-sensitive patients. They manufacture generics and biosimilars at lower costs to gain market share. This strategy is helping them expand their customer base.
• Small-Scale Players: New entrants are identifying underserved therapeutic areas and patient segments. They develop specialized products addressing unique needs. For example, firms making 3D-printed braces customized for individual joints. This niche approach helps smaller players compete against industry giants.

Emerging Startups in the Systemic Scleroderma Treatment Market:

• Innovative Technologies: Startups are coming up with novel technologies like artificial intelligence (AI) assisted disease diagnosis tools and smart injectors for targeted drug delivery. Another example is a biotech developing an oral drug that can reverse tissue fibrosis.
• Market/Impact: These emerging technologies have potential to transform current treatment landscape if successfully commercialized. The AI diagnostic solution can help identify patients early. The smart injectors can improve treatment effectiveness through controlled doses. The anti-fibrotic drug can offer patients a more convenient oral option.
• Market Contribution: Niche Markets: Agile startups are fulfilling unmet needs of subsets like pediatric patients. One example is a medical device startup developing miniature wraps for small joints in children.

Systemic Scleroderma Treatment Industry News

• On March 20, 2024, Cabaletta Bio, Inc., a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CABA-201. This investigational therapy is a fully human CD19-CAR T cell treatment containing a 4-1BB co-stimulatory domain, aimed at addressing systemic sclerosis (SSc). CABA-201 is being developed as a potential therapy for autoimmune diseases driven by B cells.
• On February 19, 2024, Certa Therapeutics, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted fast track designation for its investigational therapy FT011, aimed at treating systemic sclerosis (scleroderma). This follows the earlier Orphan Drug designation granted to FT011.
• On January 29, 2024, The Assistance Fund, an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs, announced the launch of a new financial assistance program for people living with systemic sclerosis. The program is designed to help eligible individuals pay for their out-of-pocket medical costs for treatment such as copayments, health insurance premiums, and incidental medical expenses related to the condition.

Key Takeaways from Analyst

The systemic scleroderma treatment market continues to hold strong opportunities for growth driven by the rising prevalence of the disease worldwide.

North America currently dominates the market owing to advanced healthcare infrastructure and growing awareness levels. However, Asia Pacific is expected to emerge as the fastest growing regional market in the coming years with China and India likely to spearhead demand.

High treatment costs also limit broader access in developing markets. However, the robust pipeline of drugs in clinical trials provides hope that newer targeted therapies may enter the market in the near future. A number of biologics and small molecules are under investigation that could transform the treatment landscape if approved.

Market Report Scope

Market Dynamics

Market Driver - Increasing prevalence of scleroderma

The prevalence of systemic scleroderma has been steadily rising globally, driven by genetic and environmental factors. This life-threatening connective tissue disorder affects the skin and internal organs, leading to significant health complications. The increasing patient population emphasizes the urgent need for improved treatment options to manage this non-curable condition effectively.

Market Challenge - Lack of approved drugs

The systemic scleroderma treatment market faces significant challenges due to the absence of approved drugs specifically targeting the disease. Current therapies mainly manage symptoms, while the complex pathogenesis complicates drug development. High attrition rates, lengthy development cycles, and difficulties in patient enrollment hinder clinical research, limiting treatment options and market growth. Substantial investments in R&D are essential to create effective therapies that can modify the disease's progression.

Market Opportunity - Emerging economies in Asia Pacific and Middle East

The systemic scleroderma treatment market is poised for growth in emerging economies within the Asia Pacific and the Middle East regions. Rapidly developing healthcare infrastructures, increasing medical expenditures, and heightened awareness of autoimmune disorders create lucrative opportunities. Local pharmaceutical companies are actively licensing innovative drug candidates, while favorable regulations and lower development costs attract international firms for clinical trials, enhancing global drug development contributions. This evolving landscape promises long-term benefits for the systemic scleroderma treatment industry.

Key Stakeholders of Market

What does Growth in the Systemic Scleroderma Treatment Industry Mean for Different Stakeholders?

The systemic scleroderma treatment industry has multiple players with varied designations and offers multiple opportunities based on their scope of operations.

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Segmentation

•  Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
• • Immunosuppressant
  • Phosphodiesterase 5 inhibitors - PHA
  • Endothelin Receptor Antagonists
  • Calcium Channel Blockers
  • Prostacyclin Analogues
  • Others
•  Type Insights (Revenue, USD Bn, 2019 - 2031)
• • Limited Systemic Sclerosis
  • Diffused Systemic Sclerosis
  • Sine Sclerosis
• Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
• • Oral
  • Parenteral
  • Others
•  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • GSK plc
  • Certa Therapeutics
  • Aisa Pharma, Inc.
  • Corbus Pharmaceuticals
  • AbbVie, Inc.
  • Biogen
  • Novartis AG
  • AstraZeneca
  • Celgen Corporation
  • ONO PHARMACEUTICAL CO., LTD.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH.
  • MediciNova, Inc.